PETS:NSD-PetMed Express Inc (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 4.03

Change

-0.05 (-1.23)%

Market Cap

USD 0.08B

Volume

0.14M

Analyst Target

USD 28.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc

-0.11 (-1.18%)

USD 8.41B
HITI High Tide Inc

-0.08 (-2.71%)

USD 0.22B
MEDS Trxade Group Inc

-1.04 (-11.53%)

USD 0.01B
CJJD China Jo-Jo Drugstores Inc

-0.03 (-1.27%)

USD 0.01B
LFLYW Leafly Holdings Inc

-0.01 (-18.18%)

N/A
MDVLQ MedAvail Holdings Inc

N/A

N/A
SCNX Scienture Holdings, Inc.

-1.04 (-11.52%)

N/A

ETFs Containing PETS

BUY 0.00 % 0.95 %

N/A

N/A
WTD7:F WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

N/A

USD 0.06B
WTES:F WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

-0.13 (0.00%)

USD 0.06B
WTD7:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

-0.05 (0.00%)

USD 0.06B
WTES:XETRA WisdomTree Europe SmallCa.. 0.00 % 0.00 %

-0.07 (0.00%)

USD 0.06B
DFE:SW WisdomTree Europe SmallCa.. 0.00 % 0.00 %

N/A

N/A
DFEA:SW WisdomTree Europe SmallCa.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -46.69% 33% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.69% 33% F 18% F
Trailing 12 Months  
Capital Gain -42.43% 33% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.43% 33% F 17% F
Trailing 5 Years  
Capital Gain -82.50% 67% D+ 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.50% 67% D+ 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -29.24% 33% F 8% B-
Dividend Return -25.36% 33% F 10% F
Total Return 3.88% 50% F 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 30.83% 83% B 60% D-
Risk Adjusted Return -82.27% 33% F 8% B-
Market Capitalization 0.08B 60% D- 35% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector